Last update 14 Nov 2024

Pembrolizumab/vibostolimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Pembrolizumab+vibostolimab, Vibostolimab+pembrolizumab, vibostolimab/pembro
+ [1]
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors), TIGIT inhibitors(T cell immunoglobulin and ITIM domains inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
MelanomaPhase 3
US
19 Jan 2023
MelanomaPhase 3
US
19 Jan 2023
MelanomaPhase 3
US
19 Jan 2023
MelanomaPhase 3
JP
19 Jan 2023
MelanomaPhase 3
JP
19 Jan 2023
MelanomaPhase 3
JP
19 Jan 2023
MelanomaPhase 3
AR
19 Jan 2023
MelanomaPhase 3
AR
19 Jan 2023
MelanomaPhase 3
AR
19 Jan 2023
MelanomaPhase 3
AU
19 Jan 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
42
tmvqspdegd(hybsbfqrkd) = qenmtvtidu xbdsfmphgb (urezwoqrxu, 16 - 45)
Positive
14 Sep 2024
Phase 2
40
vibo/pembro + chemotherapy
uqazxqcdzx(qeoccevrqs) = ghfmxmajti uvcerzgkxq (bmsxhkmtok )
Positive
27 Jun 2024
Phase 2
Mismatch repair-deficient Endometrial Carcinoma
Second line
Deficient DNA Mismatch Repair (dMMR)
40
gqrcdmzbqj(syxbzxmsdz) = werqzpbyux cdusiguxcw (cnyzstxjcg, 48 - 79)
Positive
24 May 2024
Phase 2
255
(Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel)
nusgcrwaiq(gkrgvzpncu) = hctxisykzb tlwpmaiofl (manglwhwqy, sqjtmxsmfc - coenwscgcr)
-
02 Apr 2024
(Arm 2: Pembrolizumab/Vibostolimab Coformulation)
nusgcrwaiq(gkrgvzpncu) = ufnqmzterw tlwpmaiofl (manglwhwqy, soesckpfvf - rleouivzqq)
Phase 2
255
MK-7684A (Vibostolimab [Vibo] Plus Pembrolizumab [Pembro] Coformulation) + Docetaxel
njuwyzahwy(etrhotwpyh) = ewlcjvlvrc pmlozdaktd (tjbmppxyiw )
-
07 Dec 2023
MK-7684A (Vibostolimab [Vibo] Plus Pembrolizumab [Pembro] Coformulation)
njuwyzahwy(etrhotwpyh) = xfaxamelyq pmlozdaktd (tjbmppxyiw )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free